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3D spheroid models of paediatric 
SHH medulloblastoma mimic 
tumour biology, drug response 
and metastatic dissemination
Sophie J. Roper1, Franziska Linke1, Paul J. Scotting2 & Beth Coyle1*
Studying medulloblastoma, the most common malignant paediatric brain tumour, requires simple 
yet realistic in vitro models. In this study, we optimised a robust, reliable, three-dimensional (3D) 
culture method for medulloblastoma able to recapitulate the spatial conformation, cell–cell and 
cell–matrix interactions that exist in vivo and in patient tumours. We show that, when grown under 
the same stem cell enriching conditions, SHH subgroup medulloblastoma cell lines established 
tight, highly reproducible 3D spheroids that could be maintained for weeks in culture and formed 
pathophysiological oxygen gradients. 3D spheroid culture also increased resistance to standard-
of-care chemotherapeutic drugs compared to 2D monolayer culture. We exemplify how this model 
can enhance in vitro therapeutic screening approaches through dual-inhibitor studies and continual 
monitoring of drug response. Next, we investigated the initial stages of metastatic dissemination 
using brain-specific hyaluronan hydrogel matrices. RNA sequencing revealed downregulation of cell 
cycle genes and upregulation of cell movement genes and key fibronectin interactions in migrating 
cells. Analyses of these upregulated genes in patients showed that their expression correlated 
with early relapse and overall poor prognosis. Our 3D spheroid model is a significant improvement 
over current in vitro techniques, providing the medulloblastoma research community with a well-
characterised and functionally relevant culture method.
Medulloblastoma is the most common malignant paediatric brain tumour, accounting for around 10% of cancer-
related deaths in  children1. Although once regarded as a single tumour entity, it is now widely accepted that there 
are four distinct molecular subgroups of medulloblastoma (WNT, SHH, Group 3, and Group 4), which differ 
in their patient demographics, metastatic potential, and  prognosis2,3. All medulloblastoma tumours are catego-
rised as Grade IV, irrespective of their histological or molecular characteristics, attesting to their malignant and 
aggressive behaviour. In addition, advances in molecular and genetic profiling have shown considerable inter-
tumoral heterogeneity in medulloblastomas and highlighted the need to rethink patient risk  stratification4,5. It is 
now proposed that patients are stratified into low, standard, high, and very high risk groups and that treatment 
regimens should be adjusted  accordingly6. Current treatment protocols for paediatric medulloblastoma include 
maximal safe surgical resection with a combination of craniospinal radiotherapy and adjuvant  chemotherapy7. 
Unlike in older children, the use of radiotherapy is avoided for infants (patients < 3 years of age) due to the neu-
rocognitive defects associated with radiation-induced damage to the developing  brain1. In addition, the high 
levels of toxicity of standard-of-care chemotherapeutics are driving the need to develop and assess alternative 
drugs for medulloblastoma treatment.
In order to improve our understanding of medulloblastoma tumour biology and behaviour, it is important to 
adopt a suitable culture system. The majority of in vitro experiments for medulloblastoma and other tumour types 
have been performed in two-dimensional (2D) monolayer culture. Although reproducible and amenable for high-
throughput drug screening studies, 2D culture fails to recapitulate the multi-dimensional growth, physiological 
gradients, and cell–cell interactions that exist in animal models and in patient tumours and can therefore over/
under-estimate the therapeutic efficacy of compounds. Over recent years, there have been vast improvements 
in in vitro technologies, allowing researchers to grow cancer cells in three-dimensional (3D) culture. 3D culture 
aims to mimic the characteristics observed in patient tumours to provide a more predictive model of tumour 
biology, thus filling the gap between standard 2D monolayer culture and animal models.
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There are numerous 3D in vitro modelling systems available and each of these methods have their own uses 
as well as advantages and disadvantages, as summarised in Supplementary Table S1. The 3D spheroid-based 
model, in which cell aggregates are grown in suspension, was pioneered by Sutherland et al. in the early  1970s8. 
Since then, the technique has been widely utilised in disease modelling, drug evaluation, and studying cell 
migration and  invasion9–13. Not only is this method widely accessible due to its cost effectiveness, but it is also 
easily reproducible and long-term culture is possible. While many cancer cell lines have been optimised for 3D 
spheroid  growth10, there have been limited studies utilising medulloblastoma cell lines in this  model14–19. In this 
study, we therefore aimed to respond to the need for an optimised and well-characterised 3D spheroid model 
of medulloblastoma. We demonstrate how established cell lines can be utilised in this model to study growth 
kinetics, identify differences in drug response that are only apparent in 3D culture, and model the initial stages 
of metastatic dissemination.
Results
Optimisation and characterisation of a 3D spheroid model of SHH medulloblastoma. The 
first stage in the establishment of a 3D spheroid model of medulloblastoma was to determine which genera-
tion method to adopt. The most common spheroid generation techniques are summarised in Supplementary 
Table S2. We chose a spontaneous formation method using non-adherent ultra-low attachment (ULA) round 
bottom plates. These plates have a covalently-bound hydrogel layer to effectively inhibit cellular attachment, thus 
promoting the formation of a single, highly-reproducible 3D spheroid in each well. This method was previously 
shown to be superior to traditional agar-coated plates for the spontaneous formation of 3D  spheroids10. A sche-
matic diagram summarising the 3D spheroid model of medulloblastoma is shown in Fig. 1. On day 0, cell lines 
grown in their standard culture conditions were harvested to generate a single-cell suspension and were then 
seeded into 96-well ULA plates. Cells typically formed an aggregate within 24 h and cell densities were optimised 
to produce 3D spheroids with a diameter of 250–350 µm by day 4, a size considered optimal for the establish-
ment of pathophysiological oxygen  gradients13. Having reached their optimal size on day 4, 3D spheroids were 
then suitable for use in numerous functional assays.
We tested three established SHH medulloblastoma cell lines (DAOY, ONS76, and UW228-3) for use in the 
3D spheroid model. For a cell line to be considered optimised, the 3D spheroids needed to exhibit a suitable 
morphology (a tight spheroid or compact aggregate, as described previously by Ivascu and  Kubbies20) as well as 
maintain continuous growth for at least seven days in culture (the minimum length of time to perform down-
stream experiments). To determine the optimal 3D spheroid growth conditions for the SHH medulloblastoma 
cell lines, cells were seeded at increasing densities and the average spheroid diameter on day 4 was measured 
(Supplementary Fig. S1). We demonstrated that the SHH medulloblastoma cell lines formed 3D spheroids in 
standard culture media; however, they failed to grow significantly over a seven day period. This is in contrast to 
cell lines of other tumour types which have been shown to successfully form 3D spheroids and maintain growth 
in standard serum-containing culture  media10. However, when seeded in serum-free neurosphere media, con-
taining supplements and growth factors routinely used in the culture and maintenance of neural stem cells, SHH 
medulloblastoma cell lines formed larger 3D spheroids which displayed continual growth over the same time 
period (Fig. 2a). A further six established medulloblastoma cell lines were tested for their suitability in the 3D 
spheroid model as shown in Supplementary Table S3. Some cell lines were unsuitable for this method of culture, 
despite modifications to promote the formation of a tighter 3D structure (Supplementary Fig. S2); however, five 
cell lines, including two group 3 lines (DAOY, ONS76, UW228-3, HD-MB03, and D458) were fully optimised.
We next aimed to characterise the reproducibility and growth of the SHH medulloblastoma cell lines in 3D 
spheroid culture. Coefficient of variation (CV) analysis was used to determine the uniformity of spheroids both 
within (intraplate CV) and between (interplate CV) experimental repeats. This unit of measurement has been 
routinely used to assess the reproducibility of spheroids and Sittampalam et al. suggested that less than 20% 
Figure 1.  Schematic diagram describing the establishment of the 3D spheroid model and its applications. On 
day 0, cells are harvested and seeded into 96-well ultra-low attachment, round-bottom plates at an optimal cell 
density to achieve 3D spheroids with a diameter of 250–350 µm by day 4. 3D spheroids can then be used in 
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variation in spheroid size was  acceptable21. There was minimal variation in spheroid diameter both within and 
across experimental repeats for all three cell lines (Fig. 2b). Both the intraplate (DAOY: 2.91–4.13%, ONS76: 
2.59–7.31%, UW228-3: 1.28–1.88%) and interplate (DAOY: 7.60%, ONS76: 13.33%, UW228-3: 5.67%) CV values 
calculated were all within the acceptable range (Supplementary Table S4).
One of the main advantages of 3D in vitro models is their ability to remain in culture for a longer period of 
time compared to standard 2D monolayer cultures which require passaging every 3–4 days to maintain viabil-
ity. We showed that DAOY and ONS76 3D spheroids continually grew for at least three weeks in culture and 
UW228-3 3D spheroids maintained growth for around 10 days (Fig. 2c,d). The 3D spheroid growth patterns 
are similar to those observed when these cell lines are implanted into mouse models. Our 3D model is therefore 
recapitulating similar growth patterns seen in vivo22. In addition, the DAOY and ONS76 3D spheroids developed 
physiological oxygen gradients within the structure over this time period. Immunohistochemical staining of 3D 
spheroid sections showed Ki67 expression, a marker of proliferation, throughout the spheroids on days 7 and 
14; however, there was an expression gradient by day 21 where Ki67 was restricted to the spheroid periphery 
Figure 2.  Growth characterisation of SHH medulloblastoma 3D spheroids. (a) Growth of SHH 
medulloblastoma 3D spheroids seeded at their optimal cell density in either neurosphere (red) or standard 
(blue) medium was assessed over a seven-day period. Spheroid diameter (µm) was significantly enhanced in 
neurosphere medium for all cell lines. Error bars represent the mean ± SEM of n = 3 experiments each containing 
3 replicates. Significance was calculated using two-way ANOVA analyses with Sidak’s multiple comparisons 
post-hoc test (*p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001). (b) Scatter plots displaying little variation in 3D spheroid 
diameter on day 4 over three independent experimental repeats (n = 1, 2, and 3) for the SHH medulloblastoma 
cell lines DAOY, ONS76, and UW228-3. Error bars represent the mean ± SD across plates containing 20–24 
3D spheroids. (c) Growth analysis of 3D spheroids up to 21 days in culture. Relationship between 3D spheroid 
volume (µm3) and time was assessed using Pearson’s correlation coefficient (r). Error bars represent the 
mean ± SEM (n = 4) containing 6 replicates at each time point. (d) Representative images of 3D spheroids at each 
time point are shown (scale bar 100 µm).
4
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4259  | https://doi.org/10.1038/s41598-021-83809-6
www.nature.com/scientificreports/
(Fig. 3a). Expression of CA9, a hypoxia marker, was evident after two weeks of spheroid culture and was more 
extensive by day 21, indicating the presence of a hypoxic core at these later time points (Fig. 3b).
As a final characterisation step, we analysed the expression of Hedgehog GLI pathway markers in SHH 
medulloblastoma 3D spheroids. mRNA sequencing analysis showed the expression of numerous Hedgehog GLI 
pathway genes, providing evidence that the cell lines used in this study could be categorised as SHH subgroup 
(Supplementary Table S5).
In this section, we have determined the optimal growth conditions, including culture medium and seeding 
densities, of SHH medulloblastoma cell lines in the 3D spheroid model. We have also demonstrated that these 3D 
spheroids retain markers of the Hedgehog GLI pathway are highly reproducible, suitable for longer term culture, 
and display physiological gradients consistent with spheroid size over time. Together, these characteristics make 
SHH medulloblastoma 3D spheroids an ideal model for downstream functional experiments.
SHH medulloblastoma 3D spheroids are improved models of drug response. Pre-clinical testing 
of potential therapeutic agents for cancer treatment typically involves in vitro screening of hundreds of drugs, 
with the most successful taken forward for in vivo testing. However, a significant number of drugs which pass 
in vitro tests later fail in animal models. Additionally, more than 90% of potential anticancer drugs that enter 
human trials fail to translate to the  clinic23. The development of more appropriate cellular models that recapitu-
late tumour biology could positively influence pre-clinical testing by providing a more accurate prediction of 
drug response at the earliest stage. The optimised growth conditions and identical starting sizes make the SHH 
medulloblastoma 3D spheroids ideal models for drug screening studies to allow direct comparisons across cell 
lines and drug  combinations9. Assessing drug response in 3D spheroids is possible using both size analysis and 
commercially-available viability assays as measures of efficacy. We showed that both continual size analysis and 
the endpoint CellTiter-Glo 3D cell viability assay (Promega) are comparable measures of drug response (Supple-
mentary Table S6). The decision regarding which method to adopt should therefore be based on the individual 
requirements of each experiment and whether intact 3D spheroids are required for further analysis after treat-
ment.
As standard 2D culture fails to recapitulate the multi-dimensional growth of tumours, we hypothesised that 
drug efficacy would differ between cells grown as 2D monolayers and 3D spheroids. We therefore tested the 
response of the SHH medulloblastoma cell lines in both culture conditions to four chemotherapeutic agents. 
Drugs (etoposide, vincristine, cisplatin, and lomustine) were selected on the basis that they are all currently 
used standard-of-care treatments for paediatric medulloblastoma and they differ in their mechanisms of action. 
We showed that there was a significant difference (p ≤ 0.0001) in drug response with 3D spheroids being more 
resistant to treatment compared to 2D monolayer culture in almost all cell lines and drugs tested (Fig. 4; Sup-
plementary Table S7).
We next aimed to confirm that the observed differences in drug response between 2D monolayers and 3D 
spheroids were not simply an artefact of 3D culture, but that 3D spheroids are more accurate and reliable mod-
els of drug response. To do this, we chose to focus on one of the most significant genetic prognostic indicators 
for paediatric SHH medulloblastoma: TP53 mutational status. Compared to TP53-wildtype SHH medullo-
blastoma patients, those with TP53-mutant SHH tumours have a profoundly worse  outcome24. TP53-mutated 
SHH tumours are stratified as very-high risk and account for the majority of treatment failures within the SHH 
 subgroup25. To explore whether differences in drug response between TP53-wildtype and TP53-mutated SHH 
medulloblastoma cells could be recapitulated in vitro, we utilised ONS76 cells (TP53-wildtype) and a geneti-
cally modified ONS76 cell line harbouring a dominant negative p53 mutation (TP53-mutant; ONS76 dnp53)26. 
We compared vincristine response in both cell types in 2D monolayer and 3D spheroid culture (Fig. 5a). In 2D 
monolayer culture, there was no difference in response between ONS76 wildtype and dnp53 cells (p = 0.8552). 
However, there was a significant difference in response in 3D spheroid culture, with ONS76 cells being more 
sensitive to vincristine treatment than ONS76 dnp53 cells (p < 0.0001). Together, these results indicate that 3D 
spheroid culture is able to identify differences in drug response that are not evident in 2D monolayer culture.
So far, we have demonstrated the testing of single compounds in the 3D spheroid model; however, it is possible 
to test inhibitor combinations. To demonstrate this approach, we aimed to potentiate the effects of vincristine 
through combined treatment with vardenafil, an inhibitor of the multi-drug transporter ABCB1 (for which 
vincristine is a  substrate27). ONS76 3D spheroids were treated with vincristine (1 nM; the measurable concen-
tration in patient  CSF28) and/or vardenafil (10 µM; the effective concentration as shown by Othman et al.29) for 
72 h, after which 3D spheroid volume was measured. There was no difference in volume after vardenafil-only 
treatment in comparison to the vehicle-treated control, therefore showing that vardenafil itself does not affect 
spheroid viability. However, the effects of vincristine were significantly potentiated when treated in combination 
with vardenafil compared to vincristine treatment alone (p ≤ 0.0001; Fig. 5b(i)). Continual monitoring of the 
effects of vincristine versus combined vincristine and vardenafil treatment showed enhanced potentiation of 
dual-inhibitor therapy over a longer period of time (Fig. 5b(ii)). The same response was also observed for DAOY 
3D spheroids (Supplementary Fig. S3). These results not only demonstrate how the 3D spheroid model can be 
used to monitor drug combinations over time but are also of substantial clinical importance as they highlight 
the improved efficacy of low dose vincristine when treated in combination with vardenafil.
We have shown that drug response differs in 3D spheroids compared to traditional 2D monolayer culture. We 
confirmed that this model can identify differences in drug response that would be missed in standard 2D culture 
studies and highlighted the benefits of monitoring drug response over a longer time period. SHH medulloblas-
toma 3D spheroids are therefore robust, reliable and improved models for therapeutic screening approaches.
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Figure 3.  Immunohistochemical staining of SHH medulloblastoma 3D spheroids for markers of proliferation 
and hypoxia. DAOY and ONS76 3D spheroids were harvested on days 7, 14, and 21, sectioned, and stained 
with markers of (a) proliferation (Ki67) and (b) hypoxia (CA9) (scale bar 100 µm). For both cell lines, Ki67 
expression was visible throughout the 3D spheroid on days 7 and 14, but expression was restricted to the 
periphery by day 21. CA9 core expression was present by day 14 and became more extensive by day 21.
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Figure 4.  Response to standard-of-care chemotherapeutics in 2D monolayer versus 3D spheroid culture. 
DAOY, ONS76, and UW228-3 medulloblastoma cell lines were treated with increasing concentrations of (a) 
etoposide, (b) vincristine, (c) cisplatin, and (d) lomustine in both 2D monolayer (blue) and 3D spheroid (red) 
culture for 72 h. The CellTiter-Glo 3D cell viability assay was performed to compare responses and viability was 
calculated as a percentage of the vehicle-treated controls. Dose response curves were generated using non-linear 
regression analyses and error bars represent the mean ± SEM of n = 3 experiments each containing 3 replicates.
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Genes upregulated in our 3D spheroid migration model are associated with fibronectin, poor 
prognosis and early relapse in SHH medulloblastoma patients. The predominant mode of medul-
loblastoma metastasis is leptomeningeal  dissemination30. SHH medulloblastomas typically spread across the 
leptomeningeal surface; however, the mechanisms by which this occurs is poorly understood. The initial stages 
of tumour spread generally involves the alteration of the cell’s cytoskeleton, increased cell motility, and inter-
action with the surrounding extracellular matrix (ECM). It is possible to study these cell–cell and cell–ECM 
interactions in vitro using 3D spheroids by modelling their migration across different matrices in order to gain 
insights into the processes involved in tumour  spread13.
Numerous commercially-available matrices such as Matrigel and Basement Membrane Extract have been 
used for modelling cancer cell migration in many tumour types. However, these matrices are prone to batch 
variability and their full composition is confidential. Instead, the use of a simple, one-component, modifiable 
matrix would be more suitable for establishing a robust technique for modelling tumour cell dissemination. In 
this study, we chose to utilise a hyaluronan (hyaluronic acid; HA) hydrogel for modelling 3D spheroid migra-
tion. HA is a major constituent of the brain  ECM31,32 and therefore serves as a tissue-relevant matrix, with the 
additional advantage that this matrix can be modified to mimic the brain’s stiffness.
A schematic diagram describing the tumour cell dissemination model of 3D spheroid migration across HA 
hydrogels is shown in Fig. 6a. 3D spheroids were generated as described and on day 4, were transferred to HA 
hydrogel-coated flat-bottomed 96-well plates. Cell migration from the 3D spheroid across the matrix was then 
assessed over a 72 h period. DAOY and ONS76 cells actively migrated from the main spheroid body and across 
Figure 5.  TP53 and ABCB1 modulated drug response can be modelled in 3D spheroids. (a) ONS76 (blue) and 
ONS76 dnp53 (red) cell lines were treated with increasing concentrations of vincristine in both 2D monolayer 
(i) and 3D spheroid (ii) culture. The CellTiter-Glo 3D cell viability assay was performed to compare responses 
and viability was calculated as a percentage of the vehicle-treated controls. There was a significant difference 
in drug response between the cell lines in 3D, but not 2D, culture. Dose response curves were generated using 
non-linear regression analyses and error bars represent the mean ± SEM of n = 3 experiments each containing 
3 replicates. (b) (i) ONS76 3D spheroids were treated with vincristine (VCR; 1 nM) in combination with 
vardenafil (VAR; 10 µM) for 72 h. Images were taken immediately after treatment to measure changes in 
spheroid volume relative to the vehicle-treated control. There was no difference in volume after vardenafil-
only treatment. Vincristine efficacy could be potentiated when treated in combination with vardenafil. Error 
bars represent the mean ± SEM of n ≥ 3 experiments each containing 3 replicates. Significance was calculated 
using one-way ANOVA analyses with Sidak’s multiple comparisons post-hoc test (ns = not significant, 
****p ≤ 0.0001). (ii) Continual monitoring of the effects of combined vincristine and vardenafil treatment (blue) 
showed a significant continual reduction in spheroid volume following treatment compared to vincristine 
alone (red). Significance differences between single and combination treatment were calculated using repeated 
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the HA hydrogel within 24 h and continued to migrate after 72 h (Fig. 6b). However, migration was limited for 
the non-metastatic UW228-3 3D spheroids.
Having established that DAOY and ONS76 3D spheroids migrate across HA hydrogels, we then used next-
generation sequencing (NGS) technologies to gain an insight into the global gene expression changes occurring 
in this 3D spheroid migration model. More details regarding sample preparation and the approaches adopted for 
NGS are included in the Supplementary Methods S1. Differential gene expression analysis revealed the upregula-
tion of genes associated with cell movement (Fig. 7a,b) and the downregulation of cell cycle processes (Supple-
mentary Fig. S4) in the 3D spheroid migration model compared to spheroids grown in suspension. Lists of the 
up- and down-regulated genes and associated gene sets identified in this analysis are included in Supplementary 
File S1. Evaluation of the list of upregulated genes in the 3D spheroid migration model identified numerous genes 
associated with the ECM component fibronectin (FN) that have been previously linked to increased cancer cell 
movement. These genes include NOTCH133, PAX634, and SOX235. In order to validate the functional relevance of 
FN on cell migration, we compared the migratory patterns of DAOY and ONS76 3D spheroids on HA matrices 
with and without FN. Collagen I (COL) was included as a control ECM component as it has been utilised in 
previous studies of medulloblastoma migration and invasion  patterns18,36. The addition of FN to the HA matrix 
significantly enhanced cell dissemination in both cell lines compared to HA and HA + COL matrices (Fig. 7c, 
Supplementary Fig. S5), highlighting a potential role for FN in medulloblastoma migration and metastasis.
In order to assess whether the spheroid migration model is representative of patient disease and outcome, 
we analysed the Cavalli medulloblastoma  dataset4 using the R2 Genomics Analysis and Visualization Platform. 
We took the lists of shared up- and down-regulated genes identified in Fig. 7 and performed k-means clustering 
Figure 6.  Modelling tumour cell dissemination on hyaluronan hydrogels using 3D spheroids. (a) Schematic 
diagram describing the hyaluronan (HA) spheroid migration model. Cells were seeded on day 0 and the 
resulting 3D spheroids were transferred to 96-well flat-bottom plates coated with HA hydrogel. Cell migration 
from the 3D spheroid across the HA hydrogel surface is then visualised over time. (b) Representative images 
of DAOY, ONS76, and UW228-3 3D spheroids migrating across HA hydrogels over a 72 h period. Images 
of the same 3D spheroid at different time points are shown (scale bar 100 µm) and are representative of n = 3 
experiments each containing 3 replicates.
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analysis to separate a cohort of SHH medulloblastomas (n = 223) into two clusters (Fig. 8a). For the 500 upregu-
lated genes, the two clusters significantly differed in their overall survival, with a worse outcome associated with 
patients stratified in cluster 2 (p = 0.022; Fig. 8b). This cluster consisted of predominantly infants (aged 0–3 years) 
and young children (aged 4–10 years) (Fig. 8c). In addition, almost all SHH-β tumours, the most aggressive 
subtype associated with metastatic disease and poor outcome, were present in cluster 2 (Fig. 8d). These findings 
suggest that the upregulated genes we identified in our 3D spheroid migration model can predict poor survival 
and early relapse in patients. The same analysis when conducted for the genes downregulated in the 3D spheroid 
migration model, did not associate with any of the above features, as shown in Supplementary Fig. S6.
We also examined the expression of stemness-related genes in the spheroid migration model. Cancer stem 
cells represent an important subpopulation of cells within a tumour with self-renewal and differentiation capaci-
ties, and also play a role in therapy resistance. Supplementary Table S8 details expression data of genes associated 
with neuronal stem cell population maintenance. Interestingly, DAOY and ONS76 migrating spheroids exhibited 
upregulation of key stem cell markers including DLL1, HES5, JAG1, NOTCH1, PCM1, SOX2, and SRRT . Elevated 
expression of some of these genes, including the Notch target gene HES5 and Notch ligand JAG1, were correlated 
with poor survival in SHH patients (Fig. 8e,f).
We conclude that the 3D spheroid migration model of SHH medulloblastoma recapitulates a migratory and 
stemness phenotype that is reflective of patient disease and prognosis.
Discussion
3D in vitro culture techniques have been widely described over the past few decades. These cellular models more 
accurately reflect the spatial conformation of patient tumours and are therefore considered more predictive mod-
els of tumour biology than conventional 2D culture methods. In this study we aimed to respond to the need for 
a robust, reliable and optimised 3D culture technique for SHH medulloblastoma to be utilised in growth assays 
and drug response studies. In addition, we sought to model tumour spread using a brain-specific HA hydrogel 
and correlate gene expression patterns with patient outcome.
Our decision on which 3D in vitro culture method to adopt was centred around their suitability for use in the 
numerous functional assays we wished to perform. Scaffold-based models, in which cells are embedded within 
a gel or matrix, are ideal for studying cell adhesion and matrix remodelling. In addition, these matrices can be 
incorporated into transwell-based assays, featuring two chambers separated by a semi-permeable membrane 
with a chemotactic gradient, to study cell migration and invasion. One of the main advantages of scaffold-based 
models is the ability to choose organ-specific matrices for the long-term culture of cells. However, this method 
is expensive, especially when scaled up to higher throughput drug screening approaches. Instead, we chose 
to adopt a 3D spheroid-based model for our study. This technique comprises of cell aggregates grown in a 3D 
conformation and can be much more cost-effective than scaffold-based culture techniques. Although there are 
numerous methods of spheroid generation, we chose to adopt a spontaneous formation method which utilises 
non-adherent surfaces to allow the formation of 3D spheroids from single cells. One of the main advantages of 
this method is its accessibility as the only specialised equipment required is an ULA plate, unlike other generation 
techniques requiring expensive rotary cell culture systems. These ULA plates produce a single 3D spheroid in 
each well, the size of which can be accurately controlled by adjusting the cell seeding density. The tight regulation 
of such experimental parameters results in the generation of highly reproducible 3D spheroids ideal for use in 
numerous experimental workflows, for example long-term growth assays, drug screening, and cell migration/
invasion assays.
Having determined the appropriate 3D culture technique, we tested a panel of widely-used medulloblas-
toma cell lines for use in the 3D spheroid model. Cell line subgroups were recently validated by Linke et al. by 
RNA  sequencing37. We firstly adopted the same spheroid generation method and culture conditions described 
by Vinci et al.10 and found that, unlike cell lines of other tumour types, SHH medulloblastoma cell lines form 
3D spheroids but fail to grow in serum-containing medium. This gave us the opportunity to test a universal 
medium which would permit standardised growth conditions across cell lines to allow direct comparisons. We 
chose to test 3D spheroid formation and growth in “neurosphere medium”, serum-free medium with additional 
supplements and growth factors, similar in composition to previously published medulloblastoma neurosphere 
culture  media38,39. In these conditions we observed a significant difference in 3D spheroid growth, with the three 
SHH cell lines tested all forming larger spheroids in neurosphere media compared to standard culture media 
and maintaining continual growth for at least seven days. Importantly, cell seeding densities were optimised to 
produce 3D spheroids with a diameter of 250–350 µm by day 4, the optimal size for the establishment of patho-
physiological oxygen  gradients13. For all cell lines tested, low cell numbers (ranging from 200 to 1500 cells per 
well) were required for the formation of suitably sized 3D spheroids. Compared to another study which utilised 
DAOY cells in a hanging drop 3D spheroid model and required 45,000 cells per  droplet40, the low cell numbers 
optimised in our model can easily be scaled up for high-throughput studies. Preliminary results show that SHH 
medulloblastoma 3D spheroids can be easily cultured in 384-well ULA plates at the same seeding densities 
optimised in this study (Supplementary Fig. S7).
We observed differences in spheroid formation ability and morphology across medulloblastoma subgroups. 
SHH cell lines, which grow adherently in standard culture, formed tight, uniform, and highly reproducible 
spheroids. However, Group 3 and 4 cell lines, which normally grow semi-adherently or in suspension, required 
additional modifications to tighten their structure or were unsuitable for culture. The observed variation in 3D 
spheroid morphology across cell lines may therefore reflect the underlying phenotype of each cell type. It was 
previously shown that more aggressive, invasive cell lines are more likely to form looser 3D  structures41. Although 
their morphology may reflect the clinical characteristics and behaviour of such tumours, the use of these 3D 
spheroids in downstream functional experiments is difficult as loose aggregates typically fall apart when under 
10
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manipulation. Cells which grow predominantly adherently in standard culture seem more likely to form suit-
able spheroids. The adhesive characteristics of these cell lines in standard culture may promote stronger cell–cell 
interactions in a 3D environment which leads to the formation of a tighter spheroid structure. This observation 
should be tested across other cell lines in order to conclude whether standard cell culture phenotype is a true indi-
cator of expected spheroid morphology. Although some of the cell lines tested did not form tight 3D spheroids, 
additional supplementation to the culture medium may promote the formation of a more compact  aggregate42,43.
We demonstrated that SHH medulloblastoma cell lines formed highly reproducible 3D spheroids, making 
them amenable for drug screening  assays9. We showed that there was a significant difference in drug response 
with 3D spheroids being more resistant to treatment compared to 2D monolayer culture in almost all cell lines 
and drugs tested. This indicated that these shifts in response were unlikely to be drug or cell line specific, but 
more likely due to the differences in the cellular structures and architecture of the 2D and 3D cultures. Unlike 2D 
monolayer culture, where cells are exposed to equal levels of nutrients, oxygen, and waste products, the spatial 
conformation of 3D spheroids generates pathophysiological  gradients44. An oxygen gradient is established during 
spheroid growth, with the oxygen availability decreasing with increasing spheroid  depth45. A low oxygen environ-
ment can reduce the cytotoxic effects of some drugs, e.g. cisplatin, and may account for the shift in response in 
3D spheroid  culture46. Oxygen depletion in the spheroid core can cause a shift to anaerobic metabolism, result-
ing in the accumulation of the by-product lactate within the 3D  spheroid46. In solid tumours and spheroids, 
the lactate production results in an acidic environment. For weak basic drugs including vincristine, this results 
in protonation (the addition of a proton making the drug positively-charged)47 and a reduction in uptake as 
charged drugs are not as effective in bypassing the cellular membrane. Swietach et al. demonstrated this effect in 
HCT-116 colon cancer spheroids and showed that the uptake of doxorubicin decreased in acidic regions of the 
 spheroid48. This pH gradient within the 3D spheroid could have contributed to the shift in drug response in the 
SHH medulloblastoma cell lines tested. An alternative mechanism of drug resistance in 3D spheroid culture is 
through cell dormancy, where the lack of oxygen and nutrients and a low pH environment induces quiescence or 
senescence. DNA damaging agents, for example cisplatin, carboplatin, and doxorubicin, exert their antitumoral 
effects in actively growing  cells49. Therefore, the non-proliferative state of dormant cells within the spheroid 
structure may account for shift in response. In addition, analysis of stemness markers in our RNAseq dataset 
showed that our 3D spheroid models express SOX2, which has been linked to quiescence and therapy resistance 
in SHH  medulloblastoma50 and could therefore account for some of the drug resistance observed. However, it 
would be important to distinguish between drug resistance and a lack of drug penetration in future studies. This 
could be achieved by fluorescently-labelling compounds and visualising their penetration through the spheroid 
structure. This technique has been successfully used to study drug and nanoparticle  penetration51,52 and our 3D 
spheroid model would be ideally suited for this application. There is also the potential to adopt higher throughput 
techniques for drug screening, for example the use of automated imaging systems and the use of 384-well ULA 
plates (Supplementary Fig. S5).
The inclusion of a genetically modified TP53-mutated cell line in our study enabled us to identify a difference 
in 3D drug response that was not evident in 2D monolayer culture. Having the ability to detect variability in drug 
response could positively influence drug screening studies, highlighting particular subgroups of patients who 
may respond differently to therapy and the adjustment of treatment regimens accordingly. We also demonstrated 
how longer term monitoring can reveal differences in drug response that could be missed in endpoint assays. 
This was particularly apparent when potentiating the effect of vincristine with the ABCB1 inhibitor vardenafil. 
In future studies, longer term drug studies could be used to continually drug treat remaining cells, generating a 
treatment-resistant 3D spheroid population.
Our final aim of this study was to model SHH medulloblastoma metastatic dissemination using 3D sphe-
roids. Although matrices such as Matrigel or BME are widely used, the exact concentration of its components 
is unknown and the resulting batch-to-batch variability is a significant drawback of the technique. In addition, 
as these matrices are derived from EHS murine chondrosarcoma tumours, they are not physiologically relevant 
for medulloblastoma tumours. Hydrogels, water-swollen networks of polymers, are alternative matrices for 3D 
culture in which cells can be placed on top of or encapsulated within the gels, making them amenable for sphe-
roid migration and invasion modelling. There has been limited research on the use of hydrogels for the culture 
of medulloblastoma cell lines. Three publications have described the use of the MAX8 β-hairpin self-assembling 
peptide hydrogels as a suitable scaffold-based model for the culture of the DAOY and ONS76 cell  lines53–55. Singh 
Figure 7.  Cell movement genes, including those associated with fibronectin interactions, are upregulated genes 
in the 3D spheroid migration model. Differential gene expression analysis was conducted to identify upregulated 
genes in the 3D spheroid migration model. (a) 500 upregulated genes (Log2 fold change ≥ 1) were shared 
between DAOY and ONS76 samples. (b) Top 10 Gene Ontology (GO) biological process gene sets significantly 
associated with these 500 upregulated genes was assessed using Gene Set Enrichment Analysis. Significances 
were determined using an uncorrected p-value and a q-value (a p-value adjusted using the Benjamini–Hochberg 
False Discovery Rate approach) to correct for multiple testing. (c) Spheroid migration across hyaluronan (HA) 
hydrogels containing collagen I (COL) or fibronectin (FN) was visualised and quantified. (i) Representative 
images of DAOY and ONS76 3D spheroids migrating across the surface of hyaluronan hydrogels over a 24 h 
period. Images of the same 3D spheroid at each time point are shown (scale bar 100 µm) and are representative 
of n = 3 experiments each containing 3 replicates. (ii) Spheroid outgrowth was calculated by measuring the area 
covered by migrating cells and normalising to the initial spheroid size at 0 h. Significant differences in relative 
spheroid outgrowth were calculated using two-way ANOVA analyses with Tukey’s multiple comparisons post-
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Figure 8.  Upregulated genes in the 3D spheroid migration model are associated with poor prognosis and early relapse. The R2 
Genomics Analysis and Visualization Platform was used to analyse the Cavalli medulloblastoma dataset. (a) Heatmap showing the 
k-means clustering of 223 SHH subgroup samples into two groups (cluster 1: n = 125; cluster 2: n = 98) based on the expression of the 
500 upregulated genes in the 3D spheroid migration model. (b) Kaplan–Meier overall survival curves for clusters 1 and 2. Pie charts 
showing the age (c) and SHH subtype (d) distributions in clusters 1 and 2. Kaplan–Meier overall survival curves for the stem cell 
markers HES5 (e) and JAG1 (f) in SHH medulloblastoma patients (n = 172).
13
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et al. also described the growth of DAOY single cells on a cellulose-derived  hydrogel56. In our study, we aimed 
to adopt a brain-specific matrix to provide a more tissue-realistic in vitro model of medulloblastoma metastatic 
dissemination. As HA is the major constituent and backbone of the brain  ECM31,32, we utilised the HyStem HA 
hydrogel kit. One of the main advantages of this system is the ability to adjust the hydrogel composition concen-
trations to recapitulate the stiffness of the  cerebellum57. We also experienced no issues with assay reproducibility 
or batch variability.
The observed differences in migratory phenotype could be reflected in the clinical features of the cell lines. 
UW228-3 cells were derived from a non-metastatic tumour and although they are TP53 mutated, which classifies 
them as higher risk, their migratory behaviour suggests they are not an aggressive cell  line58. DAOY cells were 
also obtained from a non-metastatic tumour; however, following intracerebral inoculation in nude mice, the cells 
were capable of invading the brain parenchyma as well as spreading over the surface and into the  ventricles59. In 
addition, the majority of medulloblastoma migration and invasion in vitro experiments have been conducted 
with this cell line, again highlighting its ability to disseminate (reviewed by Grotzer, Neve and  Baumgartner60). 
The ONS76 cell line was derived from a tumour with metastatic disease (M2 stage), indicating that these cells 
had metastatic  potential61.
Differential gene expression analysis of the 3D spheroid migration model identified the upregulation of cell 
movement genes and the downregulation of cell cycle processes. This finding confirms that the phenotype we 
are observing is also reflected in transcriptional changes within the cells. We consider this a model of the “go 
or grow” mechanism, whereby there is a trade-off between proliferative and migratory  phenotypes62,63. Further 
evaluation of the functional relevance of the transcriptional changes in the 3D spheroid migration model led us to 
investigate the effects of FN on cell dissemination. Although previously thought to be a tumour suppressive factor, 
FN plays an oncogenic role in the surrounding stromal tissues, promoting tumour  progression64. We observed 
enhanced cell dissemination on HA matrices containing FN, compared to those containing COL or HA alone. 
Thus, our RNAseq analysis of the 3D spheroid migration model allowed us to identify a key component of the 
TME and demonstrated how this model could be used to understand its functional relevance.
Key to the development and use of in vitro models in cancer research is ensuring they are representative of 
patient disease. We combined our RNAseq analysis with publicly-available SHH medulloblastoma patient data to 
show that the 3D spheroid migration model recapitulates a migratory and stemness phenotype that is reflective 
of patient disease and prognosis. The upregulated gene list identified in this study could be used to identify those 
patients with a particularly poor outcome, with the Kaplan–Meier analysis showing a significant drop in overall 
survival within the first 2–3 years. RNAseq analysis of stemness-related genes highlighted the upregulation of 
Notch-related genes which were also shown to be associated with poor survival in SHH medulloblastoma cases. 
These markers have been previously reported for their role in SHH  medulloblastomas65–67 and our 3D spheroid 
model would be ideal for future studies involving the Notch signalling pathway.
In this study, we have presented a robust and reliable 3D spheroid model of SHH medulloblastoma for the 
study of tumour growth, drug response, and metastatic dissemination. 3D in vitro models are not entirely new 
to the medulloblastoma research community. Some studies have relied on neurosphere culture approaches, 
whereby clusters of cells are grown in suspension, producing spheres of varying sizes and shapes, making their 
applicability to growth assays and drug screening studies  limited38,39,68. Ivanov et al. used UW228-3 3D sphe-
roids in co-culture with human neural stem cells and demonstrated their use in drug delivery  assessment14,15. 
In addition, the Baumgartner group have utilised medulloblastoma 3D spheroids to quantify cell  motility17 and 
have also used ex vivo cerebellar brain slice culture systems to study cell  migration16,18. Recently, sophisticated 
3D hydrogel-based models of medulloblastoma were developed by Linke et al. which were capable of identifying 
subgroup differences and ECM subtypes predictive of patient  outcome37. We provide an additional 3D in vitro 
model which we hope will be widely adopted by fellow researchers as not only has it been well-optimised, but it 
is also cost-effective and simple to set up and maintain. Despite the advantages of adopting a simplistic in vitro 
model, the main limitation of this study is a lack of tumour complexity in relation to the TME, which consists of 
many different cell types in addition to tumour cells, including fibroblasts, immune cells, pericytes and  ECM69. 
The TME influences each stage of tumorigenesis, from initiation to progression and metastasis. Ultimately, it 
will be important to validate the key findings derived from this model in more complex in vivo models to fully 
investigate the clinical impact of these results.
There is a huge potential for this 3D spheroid model to be expanded to include additional TME compo-
nents, including astrocytes, leptomeningeal cells, macrophages, and other ECM components, growth factors or 
 scaffolds18,70,71. By starting with a robust, established 3D spheroid model, other researchers have the flexibility 
to test primary cells, as well as customising it to build more complex models depending on their interests and 
experimental questions. In conclusion, our 3D spheroid model of SHH medulloblastoma is a significant improve-
ment over standard in vitro culture techniques and is reflective of patient disease and outcome.
Methods
Cell lines and standard culture conditions. DAOY and D283 cell lines were obtained from ATCC 
(Manassas, USA), ONS76 and ONS76 dnp53 from Annette Künkele (Charité Universitätsmedizin, Berlin, Ger-
many), UW228-3 and D458 from John R. Silber (University of Washington, Seattle, USA), HD-MD03 from Till 
Milde (DKFZ, Heidelberg, Germany), D425 from Marcel Kool (DKFZ, Heidelberg, Germany), and CHLA-01-
MED and CHLA-01R-MED from Geoff Pilkington (University of Portsmouth, UK). DAOY, D283, D425, and 
D458 cells were cultured in DMEM with 10% FBS. UW228-3 cells in DMEM/F-12 with 15% FBS and 1% sodium 
pyruvate. ONS76, ONS76 dnp53, and HD-MB03 cells were cultured in RPMI 1640 WITH 10% FBS. CHLA-01-
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3D spheroid generation and culture. Cell lines were grown in their standard culture conditions, har-
vested, and dissociated into single cell suspensions for spheroid generation. Cells were seeded in their optimal 
conditions in ultra-low attachment (ULA) round-bottom 96-well plates (Corning, 7007) in a volume of 200 µL/
well in universal neurosphere culture medium (DMEM/F-12, 2% B-27 supplement, 1% N-2 supplement, 2 µg/
mL Heparin, 20 ng/mL EGF, and 10 ng/mL bFGF, made fresh weekly). The outer wells of the ULA plate were 
filled with HBSS to reduce the effects of evaporation. Plates were incubated at 37 °C in 5%  CO2 and high humid-
ity and spheroids were maintained by performing 50% medium replenishments every 3–4 days.
3D spheroid analysis. Spheroid images were taken on a camera (Canon, DS126431) attached to a bright-
field microscope (Olympus, CKX41) at 10X magnification. The scale of images was determined using a calibra-
tion slide. A macro developed by Ivanov et al.14, compatible with the open-access software ImageJ (Fiji), was 
used for spheroid size analysis. The macro automatically calculated spheroid area and drew a blue outline of the 
detected spheroid. When the macro failed to detect the correct spheroid circumference, manual outlining was 
performed. Spheroid area (A) measurements were exported to Microsoft Excel and additional dimensions were 
calculated, including:
To calculate the coefficient of variation (CV), day 4 spheroids were imaged, analysed, and variability in sphe-
roid diameter was calculated using the following equation:
Immunohistochemistry. Day 7, 14, and 21 spheroids were pooled into separate 1.5 mL microcentrifuge 
tubes, medium was removed and spheroids were washed with 1 mL of HBSS. The wash was removed and sphe-
roids were resuspended in 500 µL of HistoGel (prewarmed to 60 °C). Spheroids in HistoGel were transferred 
to a Tissue-Tek cryomold and were rapidly cooled by placing on ice. Spheroid blocks were transferred from 
the cryomold into tissue processing cassettes, fixed in 4% paraformaldehyde for two hours, washed twice for 
10  min in PBS, and then processed. Samples were dehydrated by incubating in a series of alcohol solutions 
with increasing concentrations (one bath of 50%, 70%, 90%, and four baths of 100% methanol; one hour each), 
cleared with xylene (three baths; one hour each), and infiltrated with molten paraffin (two baths; two hours each; 
vacuum on). The following day, spheroid blocks were embedded in paraffin wax before being sectioned into 
4 µm sections. Spheroid sections were stained with primary antibodies against Ki67 (Cell Signalling Technology, 
9449; 1:400) and CA9 (Absolute Antibody, Ab00414-1.1; 1:800) in combination with a goat anti-mouse second-
ary antibody (Abcam, ab214879). Slides were counterstained with Harris Modified haematoxylin and mounted 
before imaging.
Drug response studies. Drug response was assessed in cell lines grown as 2D monolayers and 3D sphe-
roids. For 2D monolayer drug response analysis, cells were harvested when they reached approximately 70% 
confluence and seeded at a density of 1000 cells/well in black-walled 96-well plates. Cells were left to adhere 
overnight before drug treatment. For 3D spheroid drug response analysis, spheroids were generated in black-
walled 96-well ULA plates (Corning, 4520) to avoid transfer after treatment. Spheroids were drug treated on 
day 4. At the point of drug treatment, 50% of medium was removed from each well and replaced with media 
containing drug at 2 × concentration. Following 72 h of drug treatment, CellTiter-Glo 3D reagent (Promega) was 
added to each well at a 1:1 ratio. The plates were shaken at 250 rpm for 5 min in an orbital incubator to promote 
cell lysis, followed by an additional 25 min incubation at room temperature. Luminescence was measured on a 
FLUOstar Omega plate reader. Drug response was calculated as a percentage of the vehicle-treated control and 
dose–response curves and  IC50 values were generated by non-linear regression analysis.
3D spheroid drug response was also assessed by measuring changes in spheroid volume. To do this, cells were 
seeded on day 0 and the resulting 3D spheroids were drug treated on day 4 for 72 h. A complete medium replace-
ment was not performed after treatment as manipulation to the spheroids resulted in cell loss and disruption. 
Instead 50% medium replenishment, resulting in a 1:2 dilution of the remaining drug and residual drug activ-
ity, was performed as is considered acceptable in spheroid-based drug  assays9. To measure changes in spheroid 
volume, images were taken pre-treatment (day 4), during treatment (days 5 and 6), and post-treatment (days 7, 
10 and 13). Significant differences in volume between the vehicle- and drug-treated spheroids were calculated 
using repeated measures two-way ANOVA analyses with Dunnett’s multiple comparisons post-hoc test.
Hyaluronan hydrogel migration models. Hyaluronan hydrogels were prepared according to the manu-
facturer’s instructions (HyStem hydrogel kit; ESI-BIO, GS311). A hydrogel with a stiffness around 1.5–2 kPa, 
within the range of normal brain tumour  stiffness72, was produced by making a 1% Glycosil (thiol-modified HA) 
and 2% ExtraLink-Lite (PEGDA) solution. Collagen I (Cultrex, 3447-020-01), and fibronectin (Cultrex, 3420-
001-03) were added to hyaluronan hydrogels at a concentration of 50 µg/mL. For HyStem migration experi-
ments, 50 µL of diluted hydrogel was added to each well of a tissue-culture treated 96-well plate and the solution 
was spread evenly over the well’s surface. The hydrogel-coated plates were incubated at 37 °C for 30 min to allow 
the gel layer to set. Day 4 spheroids were then transferred from the 96-well ULA plate in which they were gener-
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medium was added to each well and plates were incubated at 37 °C for 1 h to allow the spheroids to settle on the 
matrix. Spheroid migration across HyStem hydrogels was assessed by manual imaging over a 72 h period. Rela-
tive spheroid outgrowth was calculated by measuring the area covered by migrating cells and normalising to the 
initial spheroid size at 0 h. Significant differences in relative spheroid outgrowth were calculated using two-way 
ANOVA analyses with Tukey’s multiple comparisons post-hoc test.
Next-generation sequencing. Ten wells per condition were harvested and pooled into a 1.5 mL micro-
centrifuge tube and snap-frozen in liquid nitrogen and stored at −80 °C. RNA isolation was performed using 
the NucleoSpin RNA Plus kit (Macherey–Nagel, 740984). Samples were transferred to tubes containing lysing 
Matrix D beads (MP Biomedicals, 11412420), 1.4 mm ceramic spheres used for grinding matrices. 350 µL of 
lysis buffer was added to each tube and samples were homogenised for 30 s using a Fast-Prep24 tissue homog-
eniser (MP Biomedicals, 12079310). Samples were then transferred to a new 1.5 mL microcentrifuge tube and 
centrifuged at 11,000×g for 5 min to pellet the hydrogel at the bottom of the tube. The rest of the extraction was 
performed according to the RNA isolation kit manufacturer’s instructions. Next-generation sequencing (NGS) 
was performed by QIAGEN Genomic Services (Hilden, Germany). More details regarding the NGS technologies 
adopted are included in the Supplementary Methods S1.
Patient dataset analysis. K-means clustering and Kaplan–Meier survival analysis was performed on the 
R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl) using the Cavalli medulloblastoma  dataset4.
Data availability
The RNA sequencing data have been deposited in the ArrayExpress database at EMBL-EBI (http://www.ebi.
ac.uk/array expre ss) under accession number E-MTAB-10127.
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